Compounds that select against the tetracycline-resistance efflux pump

Area of Science:

• Microbiology
• Pharmacology
• Genetics

Background:

• Antibiotic resistance poses a significant global health threat.
• Efflux pumps, like TetA, are key mechanisms conferring resistance.
• Novel strategies are needed to overcome existing antibiotic resistance.

Purpose of the Study:

• To develop a screening method for identifying compounds that reverse antibiotic resistance.
• To discover novel compounds that select against the TetA tetracycline-resistance efflux pump.
• To evaluate the potential of identified compounds for combination therapy.

Main Methods:

• Developed a competition-based screening assay.
• Screened a library of over 19,000 compounds against Escherichia coli expressing TetA.
• Identified and validated hit compounds through secondary assays.

Main Results:

• Identified two compounds, β-thujaplicin and disulfiram, that select against TetA-mediated tetracycline resistance.
• Demonstrated that β-thujaplicin treatment selects for the loss of the tetracycline resistance gene.
• Showcased the potential for a sequential treatment approach using β-thujaplicin followed by doxycycline.

Conclusions:

• A novel screening strategy successfully identified compounds that invert antibiotic resistance.
• β-thujaplicin represents a promising candidate for combating tetracycline resistance.
• This approach offers a new paradigm for overcoming antibiotic resistance through combination therapy.